Top Psychedelic Therapy Providers: A 2026 Guide

What is Psychedelic Therapy?

Psychedelic therapy pairs a psychedelic or psychedelic-like medicine with a defined therapeutic process to treat mental health conditions like anxiety, depression, and PTSD. Neither half does the job alone. The medicine temporarily leverages neuroplasticity to open a window in which entrenched patterns of thought and behavior become more flexible, and the surrounding process, known as the psychedelic modality, is what turns that window into lasting change.¹

The modality has a defined shape: setting an intention, preparing before the session, a supported dosing session in an intentional setting, and integration work afterward. It is the same structure used in the major psychedelic research trials, and it is the reason two providers offering the same medicine can produce very different results. That is why not all providers deliver the same level of care.

What Makes a Psychedelic Therapy Provider "Top"?

"Top" has little to do with brand recognition or marketing spend when it comes to psychedelic therapy. One of the key factors is whether the medicine sits inside a real clinical and therapeutic system, or is simply handed over. The best providers treat the medicine as necessary but not sufficient and build rigor around it, so outcomes are more predictable and safety is accountable. Several markers, taken together, separate them:

• Medical screening and eligibility assessment: A licensed provider must evaluate your medical and psychiatric history to confirm you are an appropriate candidate.
• Licensed medical oversight: Prescribing and ongoing monitoring should be managed by qualified physicians or specialists.
• Emphasis on the psychedelic modality: The provider must include preparation and integration support, not just the dosing session.
• Published outcomes data: Top providers publish peer-reviewed research demonstrating their protocol's effectiveness.
• Transparent safety reporting: The provider should clearly report side effect rates and adverse events.
• Clear informed consent: You should receive a thorough explanation of potential risks, benefits, and what to expect.

No single marker is decisive. What sets a top provider apart is having all of them at once: the structure around the medicine is as serious as the medicine itself.

Which Conditions Do Psychedelic Therapy Providers Treat?

Psychedelic therapy providers address a range of mental health challenges, with the strongest evidence supporting care for depression, anxiety, and PTSD. A top provider will match therapy to your specific needs through a thorough evaluation process, rather than using a one-size-fits-all protocol.

The primary conditions addressed across the psychedelic therapy landscape include:

• Depression: Ketamine therapy has a robust real-world evidence base for rapidly reducing symptom severity in major depressive disorder and treatment-resistant depression.
• Anxiety: Providers frequently treat generalized anxiety disorder and related conditions. The neuroplasticity induced by psychedelic medicine can help disrupt chronic worry loops.
• PTSD and trauma: Psychedelic therapy can help individuals process trauma by reducing the fear response associated with difficult memories.

Research is also expanding into additional areas, including OCD, grief, burnout, habit change, addiction, and chronic pain. Evidence strength varies by indication, but ketamine currently has the broadest legal availability and the deepest real-world evidence base across multiple conditions. Psychedelic therapy is an evidence-based option for adults experiencing these conditions, not just a last resort.

Where Psychedelic Therapy Is Legal in the United States

Ketamine is the only psychedelic substance legally available nationwide for therapeutic use today. Understanding legality by substance prevents wasted time pursuing options that are not yet available outside of research settings.

The current legal pathways include:

• Ketamine: Legal nationwide. It is available via licensed providers prescribing off-label. Care is delivered through at-home telehealth programs, in-clinic infusion centers, and some psychiatric practices. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression under a REMS program. Ketamine has been FDA-approved as an anesthetic since 1970 and has been on the WHO List of Essential Medicines since 1985. Off-label prescribing for mental health conditions is a widespread, legally accepted medical practice.³
• Psilocybin: Legal in Oregon through licensed service centers operational since 2023 and in Colorado under a developing regulated access framework. New Mexico has authorized a state medical psilocybin program under the 2025 Medical Psilocybin Act, with patient access expected to begin in late 2026. It is not available through standard medical prescriptions or compounding pharmacies.
• MDMA, LSD, and psilocybin (research): These are available only through FDA-authorized research trials at academic medical centers and research institutions. They are not commercially available.

For most people seeking psychedelic therapy today, ketamine is the most immediately accessible and evidence-supported option.

Top Psychedelic Therapy Providers by Care Model

Psychedelic therapy providers fall into distinct care model categories, each suited to different needs, preferences, and health situations. The subsections below organize the leading providers by how they deliver care so you can compare options based on what matters most to you.

At-Home Ketamine Therapy Programs

At-home ketamine therapy involves provider-prescribed sublingual tablets or subcutaneous injections administered in your own home under remote supervision. The model includes preparation and integration support. It suits adults seeking the comfort and convenience of home-based treatment, those without access to nearby clinics, and people who want a comprehensive program rather than just medication.

Leading providers in the at-home category include:

• Mindbloom: The largest provider of guided at-home psychedelic therapy in the U.S. Each program includes provider consults, guide coaching, custom soundscapes for use during sessions, and a library of psychedelic preparation and integration content. Mindbloom has published three of the largest peer-reviewed real-world outcomes studies of psychedelic medicine to date.^4,5,6 Programs are available in 6, 12, or 18 sessions.
• Joyous: The company uses a low-dose daily sublingual ketamine protocol with remote monitoring. It targets sub-perceptual dosing, which is a different approach from the psychedelic modality of therapeutic dosing, intention-setting, and integration.
• BetterU: The organization offers at-home ketamine therapy and positions itself as providing various programs for mental health.

At-home programs vary significantly in care structure, how close they are to actual psychedelic therapy, integration support, and published evidence.

In-Clinic Ketamine Infusion Clinics

In-clinic ketamine infusion clinics are brick-and-mortar medical facilities where ketamine is administered intravenously (IV) or intramuscularly (IM) under direct in-person supervision. The model suits individuals who prefer in-person medical oversight or those whose health profile requires direct monitoring.

Representative providers include:

• Ketamine Clinics of Los Angeles: One of the earliest IV ketamine clinics in the U.S.
• Ember Health: A multi-location IV ketamine clinic with standardized infusion protocols.

IV infusion clinics are typically more expensive per session than at-home programs and the utilization of the psychedelic modality varies across IV clinics. Some build the full psychedelic process into their model, others offer it as an optional add-on priced separately from the infusion itself, and some focus primarily on medication delivery. Before committing, confirm that the clinic also provides preparation, integration, and follow-up care as part of the care model.

State-Legal Psilocybin Service Centers

State-legal psilocybin service centers are licensed facilities in Oregon and Colorado where adults can receive psilocybin in a supervised setting with trained facilitators. New Mexico has authorized a medical psilocybin program launching in late 2026, but no service centers are operating there yet. These operate under state regulatory frameworks, not federal FDA approval. Candidates typically include individuals specifically seeking psilocybin-assisted experiences, those located in or willing to travel to those states, and people interested in a facilitator-guided psychedelic session outside of a traditional medical model.

These are not medical clinics and do not require a diagnosis. Sessions tend to be longer, typically 6 to 8 hours, and more expensive than at-home psychedelic therapy. Representative licensed service centers include:

• Oregon: The program has been operational since 2023 under Measure 109. EPIC Healing Eugene, the first licensed psilocybin service center in the U.S., is among roughly 20-plus active centers statewide. The full list is available via the Oregon Health Authority's Oregon Psilocybin Services Licensee Directory.
• Colorado: Regulated access launched under the Natural Medicine Health Act, with the framework still maturing. The Center Origin in Denver was the state's first licensed healing center, running its first regulated session in June 2025, with additional centers now operating in Boulder and Aspen. The full list is managed by the Colorado Department of Natural Medicine.

Psilocybin service centers represent a new legal pathway but remain geographically limited. They are not yet integrated into mainstream healthcare or insurance systems.

Psychedelic Research Trials and Academic Centers

Psychedelic research trials are FDA-authorized studies at academic medical centers testing substances like MDMA, psilocybin, LSD, or novel compounds for specific psychiatric conditions. Participation is free but requires meeting strict inclusion criteria. These trials are best suited for individuals interested in substances not yet legally available outside of research, those willing to accept randomization (including placebo-controlled groups), and people near major research institutions.

Representative institutions include:

• Icahn School of Medicine at Mount Sinai: Houses the Parsons Research Center for Psychedelic Healing, led by Dr. Rachel Yehuda.
• Johns Hopkins Center for Psychedelic and Consciousness Research: A leading institution for Phase II and Phase III trials.
• NYU Langone Psychedelic Medicine Research Group: Conducts extensive research on psilocybin and other compounds.
• MAPS (Multidisciplinary Association for Psychedelic Studies): Sponsors research trials for MDMA-assisted therapy.

Research trials offer access to substances not yet commercially available but involve strict eligibility, potential placebo assignment, and limited geographic availability. ClinicalTrials.gov is the primary resource for finding active studies.

Provider Directories and Referral Networks

Provider directories are online platforms that aggregate and list psychedelic-assisted therapists, ketamine prescribers, and integration specialists by location and specialty. These platforms are most useful for people in the early research phase who want to compare multiple providers, those looking for psychedelic-assisted therapists near them, or specialists seeking referral networks.

Notable directories in this space include:

• Psychedelic Support: A directory of psychedelic therapists, integration coaches, and ketamine providers.
• Journey Clinical: Connects clients with therapists who incorporate ketamine-assisted therapy into their practice.
• MAPS Psychedelic Integration List: A directory of therapists trained in psychedelic integration.

Directories are useful starting points for finding providers but do not independently verify treatment outcomes, safety records, or protocol quality. Use the evaluation criteria from this guide to assess any provider you find through a directory.

Research and Outcomes Data to Look For

Outcomes data includes peer-reviewed studies, real-world evidence, published safety profiles, and transparent reporting of both efficacy and adverse events. Providers who publish this data demonstrate a level of accountability that unverified marketing claims cannot match.

When evaluating a provider, look for these specific types of evidence:

• Peer-reviewed publications: Has the provider published studies in recognized journals? Look for sample sizes, measurement instruments like the PHQ-9, GAD-7, or PCL-5, and response or remission rates.
• Real-world evidence vs. research trial data: Real-world outcomes studies reflect how treatment performs in actual practice, not just in tightly controlled trial settings.
• Safety reporting: Does the provider publish side effect rates, serious adverse event rates, and discontinuation data?
• Protocol transparency: Is the treatment protocol described in enough detail to judge its rigor?

The absence of published data does not automatically mean a provider is unsafe, but it does mean you are taking their claims on faith. A provider who publishes, and reports the hard numbers alongside the flattering ones, is giving you something you can actually verify.

What to Look for in a Provider's Care Team

A care team in psychedelic therapy is the combination of prescribing physicians, therapists or guides, integration specialists, and support staff involved in your care. A provider's care team structure reveals whether treatment is medication-only or part of a comprehensive care model.

Verify the following credentials and roles when choosing a provider:

• Licensed prescribers: Who writes the prescription? Ensure they are licensed physicians, nurse practitioners, or physician assistants with relevant psychiatric or medical training.
• Therapists or guides: Does the provider include dedicated coaching or therapy support for preparation and integration, or is the program limited to medication delivery?
• Integration support: Is there a defined framework for integration after sessions, such as 1:1 coaching, group circles, or journaling frameworks, or are you left to process the experience on your own?
• Supervision and accountability: What is the supervision model? Ask how prescribers are trained in psychedelic-specific protocols.

Providers who include preparation, in-session support, and integration alongside prescribing demonstrate a more complete approach to psychedelic therapy.

How Mindbloom Delivers Clinician-Guided Psychedelic Therapy

The markers that separate a top provider, real screening, licensed oversight, the full modality, published proof, and transparent safety, are the structure Mindbloom is built around. Its at-home model is designed so the rigor of a clinical program travels into the client's home instead of being traded away for convenience.

Every program includes provider consultations for diagnosis, eligibility, and ongoing monitoring. Beyond that, Mindbloom prioritizes the psychedelic modality: 1:1 guide coaching for preparation and integration, plus a full library of custom video content and session audio built to help clients prepare for and integrate their sessions around goals like depression, anxiety, burnout, grief, and habit change. Mindbloom offers both sublingual tablets and subcutaneous injectables, making it the only at-home provider offering subcutaneous administration, and a peer treatment monitor is required for every session. Programs come in 6, 12, or 18 sessions, personalized to each client's goals.

Mindbloom is also one of the few providers to publish its outcomes in peer-reviewed journals:

• Depression: 89% of clients reported symptom improvement.⁴
• Anxiety: 89% of clients reported symptom improvement.⁴
• PTSD: 84.6% of clients reached clinically meaningful improvement, in the first peer-reviewed study of at-home PTSD outcomes.⁶

Individual results may vary. Across more than 800,000 clinician-supervised sessions, Mindbloom reports a well-documented safety profile: side effects at roughly 4 to 5% of sessions, serious adverse events at fewer than 0.1%.³

Questions to Ask Any Psychedelic Therapy Provider

The psychedelic therapy landscape includes providers with widely varying levels of scientific accountability. These questions help you distinguish comprehensive care from medication-only services.

Use your practical checklist of questions when evaluating a provider:

1. What is your medical screening and eligibility process?
2. Who prescribes the medication, and what are their credentials?
3. Is a peer treatment monitor or support person required during sessions?
4. What preparation and integration support is included?
5. Do you publish outcomes data or peer-reviewed research?
6. What are your reported side effect and adverse event rates?
7. What happens if I have a difficult experience during a session?
8. What is the total cost, and is any portion reimbursable through insurance or HSA/FSA?
9. How is my care plan personalized over time?
10. What substances do you offer, and through which routes of administration?

A provider who answers these questions transparently is more likely to deliver safe, effective care; reluctance to share safety data, team credentials, or protocol details is a signal to look elsewhere.

Next Steps Based on Your Situation

Your next step depends on your specific health needs, location, budget, and preferences. Start with the pathway that is legally available and medically appropriate for your situation.

Consider your next steps based on where you are in your journey:

• If you are ready to start psychedelic therapy from home: Mindbloom offers protocol-driven programs of 6, 12, or 18 sessions with medical oversight, guide coaching, and integration support.
• If you prefer in-clinic treatment: Search for accredited IV ketamine infusion clinics in your area and verify that they include pre-session and post-session therapeutic support, not just infusion delivery.
• If you are interested in psilocybin therapy: Check Oregon's licensed service center directory for currently operational facilities.
• If you want to participate in a research trial: Search ClinicalTrials.gov for active psychedelic studies recruiting near you.
• If you are still researching: Use a provider directory like Psychedelic Support or Journey Clinical to compare options, then apply the evaluation criteria from this guide.

Mindbloom's at-home psychedelic therapy starts at $165 per session. See the FAQ below for full pricing details.

Conclusion

The top psychedelic therapy providers are defined by scientific accountability, published outcomes, integration support, and transparent safety reporting, not by marketing claims alone. Ketamine therapy is the most widely accessible and evidence-supported option available today. Evaluating providers by the criteria in this guide helps ensure safe, effective care regardless of which modality or setting you choose.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.